TD Asset Management Inc. Sells 7,500 Shares of bluebird bio, Inc. (BLUE)

TD Asset Management Inc. reduced its stake in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 14.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,288 shares of the biotechnology company’s stock after selling 7,500 shares during the period. TD Asset Management Inc. owned about 0.11% of bluebird bio worth $4,758,000 as of its most recent filing with the SEC.

Several other large investors have also bought and sold shares of BLUE. BlackRock Inc. raised its stake in bluebird bio by 44,948.0% in the first quarter. BlackRock Inc. now owns 3,182,188 shares of the biotechnology company’s stock valued at $289,259,000 after buying an additional 3,175,124 shares in the last quarter. MARSHALL WACE ASIA Ltd purchased a new position in bluebird bio during the first quarter valued at approximately $18,006,000. Marshall Wace North America L.P. purchased a new position in bluebird bio during the first quarter valued at approximately $18,006,000. Vanguard Group Inc. raised its position in bluebird bio by 4.6% in the first quarter. Vanguard Group Inc. now owns 3,215,246 shares of the biotechnology company’s stock valued at $292,266,000 after buying an additional 141,293 shares during the period. Finally, Emerald Advisers Inc. PA raised its position in bluebird bio by 207.0% in the second quarter. Emerald Advisers Inc. PA now owns 196,174 shares of the biotechnology company’s stock valued at $20,608,000 after buying an additional 132,278 shares during the period.

Shares of bluebird bio, Inc. (BLUE) opened at 92.45 on Friday. The stock’s market cap is $4.21 billion. bluebird bio, Inc. has a 52-week low of $37.05 and a 52-week high of $123.75. The firm’s 50-day moving average is $96.49 and its 200 day moving average is $91.07.

bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.66) by $0.07. The company had revenue of $16.70 million for the quarter, compared to analyst estimates of $6.29 million. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The firm’s revenue for the quarter was up 977.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.59) EPS. Analysts forecast that bluebird bio, Inc. will post ($6.78) earnings per share for the current fiscal year.

Several research analysts recently commented on the stock. Cantor Fitzgerald set a $39.00 price objective on shares of bluebird bio and gave the stock a “sell” rating in a research note on Saturday, June 24th. Jefferies Group LLC reiterated a “buy” rating on shares of bluebird bio in a research note on Thursday, July 6th. Evercore ISI assumed coverage on shares of bluebird bio in a research note on Wednesday. They set an “in-line” rating and a $102.00 price objective for the company. Sanford C. Bernstein assumed coverage on shares of bluebird bio in a research note on Thursday, July 27th. They set a “market perform” rating and a $109.00 price objective for the company. Finally, BMO Capital Markets reiterated a “buy” rating and set a $108.00 price objective on shares of bluebird bio in a research note on Friday, August 4th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the company’s stock. bluebird bio presently has a consensus rating of “Hold” and an average target price of $100.74.

In other news, Director Daniel Lynch sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $80.00, for a total transaction of $160,000.00. Following the transaction, the director now directly owns 3,400 shares in the company, valued at $272,000. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Philip D. Gregory sold 1,500 shares of the firm’s stock in a transaction that occurred on Tuesday, June 6th. The stock was sold at an average price of $99.04, for a total transaction of $148,560.00. Following the transaction, the insider now owns 37,279 shares in the company, valued at $3,692,112.16. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 80,106 shares of company stock worth $8,308,358. Insiders own 3.90% of the company’s stock.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).